- Home
- LEGT vs ACRS Comparison
LEGT vs ACRS Comparison
Compare LEGT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LEGT | ACRS |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.6M | 230.8M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LEGT | ACRS |
|---|---|---|
| Price | $10.82 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 47.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.06 |
| P/E Ratio | $32.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.29 | $1.05 |
| 52 Week High | $11.25 | $3.57 |
Technical Indicators
Market Signals| Indicator | LEGT | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 62.90 |
| Support Level | $10.79 | $3.12 |
| Resistance Level | $10.86 | $3.48 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 63.64 | 69.49 |
Price Performance
Historical ComparisonAbout LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.